| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | CLDN18.2 |
| Clinical data | |
| Trade names | Vyloy |
| Other names | IMAB362, claudiximab, zolbetuximab-clzb |
| AHFS/Drugs.com | Vyloy |
| License data |
|
| Routes of administration | Intravenous infusion |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Zolbetuximab, sold under the brand name Vyloy, is a monoclonal antibody used for the treatment of gastric cancer.[1][4] It is a claudin 18.2-directed cytolytic antibody against isoform 2 of Claudin-18.[1] Zolbetuximab was developed by Ganymed Pharmaceuticals.[5] Astellas Pharma acquired the rights to zolbetuximab in December 2016, when it acquired Ganymed Pharmaceuticals.[6]
The most common adverse reactions include nausea, vomiting, decreased appetite, neutropenia (low levels of neutrophils, a type of white blood cell that fights infections), decreased neutrophil counts, weight loss, fever, hypoalbuminemia (low levels of albumin, a blood protein), and peripheral edema (swelling, especially of the ankles and feet).[2]
- ^ a b c "Vyloy- zolbetuximab injection, powder, for suspension". DailyMed. 18 October 2024. Retrieved 31 October 2024.
- ^ a b Cite error: The named reference
Vyloy EPARwas invoked but never defined (see the help page). - ^ "Vyloy PI". Union Register of medicinal products. 25 September 2024. Retrieved 27 September 2024.
- ^ "Astellas' Vyloy (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer" (Press release). Astellas Pharma. 26 March 2024. Archived from the original on 19 April 2024. Retrieved 19 April 2024 – via PR Newswire.
- ^ "Our mission - Ganymed Pharmaceuticals GmbH - Ganymed Pharmaceuticals GmbH". www.ganymed-pharmaceuticals.de. Archived from the original on 20 December 2013. Retrieved 20 December 2013.
- ^ "Astellas Completes Acquisition of Ganymed Pharmaceuticals". Astellas Pharma. Archived from the original on 5 August 2020. Retrieved 20 January 2023.